BrainsWay (BWAY) Q1 2026: RPO Backlog Jumps 25% as Deep TMS Adoption Accelerates
BrainsWay’s Q1 showcased a decisive inflection in recurring revenue visibility with RPO up 25% to $75 million, underpinned by robust Deep TMS system placements and expanding reimbursement. Strategic investments in new treatment protocols, minority stakes in mental health networks, and home-based neuromodulation platforms are broadening the company’s addressable market and reinforcing its position as a leader in non-pharmacologic mental health therapies. With guidance reaffirmed and margin expansion sustained, BrainsWay’s multi-pronged growth strategy is gaining traction across both U.S. and international markets.
Summary
- Backlog Expansion Signals Demand Strength: RPO climbed, reflecting multi-year contract momentum and visibility.
- SWIFT Protocol Gains Reimbursement Traction: Shorter treatment schedules and strong efficacy are driving payer adoption.
- Strategic Investments Extend Market Reach: Minority stakes and home-use devices anchor long-term growth runway.
Business Overview
BrainsWay develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS), a non-invasive neuromodulation therapy for a range of mental health conditions, including depression, OCD, and addiction. The company earns revenue by selling and leasing Deep TMS systems to clinics and hospitals, with a recurring revenue model anchored by multi-year service contracts. Its core business is complemented by strategic investments in mental health provider networks and emerging home-use neuromodulation platforms.
Performance Analysis
BrainsWay delivered a standout quarter, with revenue up 35% year-over-year, driven by a 44% increase in Deep TMS system shipments and a strengthening base of recurring contracts. The company’s total installed base reached approximately 1,820 systems, and operating leverage was evident as both net income and adjusted EBITDA more than doubled versus Q1 2025. Gross profit climbed in line with revenue, reflecting healthy margin preservation despite increased investment in sales, marketing, and R&D.
Remaining Performance Obligations (RPO), a forward indicator of contracted revenue, rose to $75 million, up 25% from the prior year, with most new deals structured as multi-year agreements. Importantly, positive operating cash flow and a debt-free balance sheet—despite $9 million in strategic investments during the quarter—underscore the sustainability of BrainsWay’s business model. International momentum complemented U.S. growth, with distributor-led expansion in Asia Pacific, Canada, and Europe contributing to order strength.
- Recurring Revenue Model: Multi-year contracts and rising RPO are driving predictable cash flow and profit expansion.
- Margin Discipline Maintained: Operational leverage supported margin growth even as investment in new protocols and clinical trials increased.
- Capital Allocation to Growth Platforms: Strategic deployment of capital into provider networks and new technologies is broadening the revenue base.
BrainsWay’s ability to execute on both core system placements and strategic initiatives is translating into sustained profitability and enhanced long-term revenue visibility.
Executive Commentary
"We view the steady increase in RPO over the past three years as a clear indicator of strong market demand—a success of our strategy focused on servicing enterprise customers while also providing greater visibility into future revenue streams."
Hadar Levy, Chief Executive Officer
"The capital structure for the company remained debt-free, giving us significant flexibility to pursue strategic growth initiatives including the various investments Adar outlined earlier."
Ido Moroni, Chief Financial Officer
Strategic Positioning
1. Deep TMS Platform Penetration
BrainsWay’s core Deep TMS platform continues to gain share from alternative therapies, supported by robust clinical evidence and expanding reimbursement. The company’s focus on enterprise customers and multi-year contracts is building a durable installed base and recurring revenue stream.
2. SWIFT Protocol Adoption
The six-day SWIFT protocol is emerging as a differentiator, with landmark data showing 88% response and 78% remission rates in just six days. Early payer adoption and new coverage policies are accelerating access, with management targeting up to 50 million covered lives by year-end.
3. Strategic Investments in Provider Networks
Minority equity investments in high-performing mental health clinics are creating synergistic growth channels, enabling BrainsWay to influence care delivery, accelerate system adoption, and share in the upside of network expansion. The pipeline of potential deals remains robust.
4. Home-Based Neuromodulation Expansion
Investment in NeuroLIF’s ProLiVarex device positions BrainsWay for home-use market entry, addressing patients unable to access in-clinic care and expanding the total addressable market. VA contract wins and milestone-based investments signal commercial traction.
5. International Growth Acceleration
Distributor-led expansion in key international markets is supplementing U.S. growth, with rising orders and new indications supporting global adoption of Deep TMS.
Key Considerations
This quarter’s results reflect strong execution against a multi-pronged strategy, positioning BrainsWay for durable growth and broader market leadership in non-pharmacologic mental health treatment.
Key Considerations:
- Enterprise Contract Focus: The shift to multi-year agreements is enhancing revenue predictability and customer stickiness.
- SWIFT Protocol Momentum: Shorter, high-efficacy protocols are driving both patient demand and payer coverage, accelerating adoption curves.
- Strategic Capital Deployment: Investments in provider networks and home-use technology diversify revenue streams and create new growth vectors.
- Clinical Pipeline Expansion: Ongoing trials for alcohol use disorder and planned PTSD indication filings could unlock new TAM and reimbursement opportunities.
- Balance Sheet Strength: Ample cash and no debt enable continued investment in R&D and commercial initiatives without financial strain.
Risks
BrainsWay remains exposed to reimbursement policy shifts, competitive innovation in neuromodulation and pharmacologic treatments, and clinical trial execution risks. While international expansion is accelerating, geopolitical instability and regulatory changes could impact distributor performance or supply chains. The company’s forward-looking statements depend on continued payer adoption, clinical validation, and successful integration of strategic investments.
Forward Outlook
For Q2 2026, BrainsWay guided to:
- Continued revenue growth driven by system placements and recurring contracts
- Ongoing margin expansion as scale and operational leverage increase
For full-year 2026, management reaffirmed guidance:
- Revenue of $66 to $68 million (27% to 30% YoY growth)
- Operating income margin of 13% to 14%
- Adjusted EBITDA of $12 to $14 million, nearly doubling 2025 levels
Management cited several drivers for confidence in guidance:
- Growing RPO and multi-year contract coverage
- Expansion of SWIFT protocol reimbursement and international distribution
Takeaways
BrainsWay’s Q1 2026 results highlight the power of its recurring revenue model, with multi-year contracts and a growing backlog anchoring future visibility. Strategic investments in new protocols, clinics, and home-use devices are expanding both the company’s reach and its relevance in a consolidating mental health market.
- RPO and Margin Expansion: Backlog growth and margin discipline are translating into sustained profitability and cash flow.
- Platform and Pipeline Diversification: Clinical pipeline progress and new channel investments are broadening the company’s future opportunity set.
- Watch SWIFT Uptake and Home-Use Adoption: Continued payer adoption of SWIFT and commercial milestones for ProLiVarex will be key indicators of long-term runway.
Conclusion
BrainsWay is executing on a balanced strategy of core platform growth, innovative clinical protocols, and strategic investments that together are driving both near-term results and long-term market leadership in neuromodulation for mental health. Investors should monitor the pace of reimbursement expansion and clinical pipeline milestones as leading indicators of future upside.
Industry Read-Through
BrainsWay’s results reinforce several industry-wide trends in mental health therapeutics: payers and providers are increasingly favoring non-pharmacologic, rapid-acting, and evidence-based treatment modalities. The success of the SWIFT protocol and traction for home-use neuromodulation devices highlight a shift toward patient-centric, accessible care models. For the broader neuromodulation and mental health tech sector, multi-year contracting, integration with provider networks, and expansion into home settings are emerging as critical success factors. Competitors and adjacent players should watch the interplay between clinical evidence, reimbursement momentum, and capital allocation to new treatment channels as the next phase of market expansion unfolds.